Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BAC and GE Healthcare Collaboration Wins Industry Award

Published: Thursday, October 11, 2012
Last Updated: Thursday, October 11, 2012
Bookmark and Share
Collaboration to develop new technologies for the cost-effective manufacture of novel biopharmaceuticals recognized as ‘Collaboration of the Decade - Downstream Processing’ at BPI Awards.

BAC BV has announced that a successful long-term collaboration with GE Healthcare, the healthcare business of GE, to develop innovative purification media for the production of novel types of biopharmaceuticals has been recognized with the “Collaboration of the Decade Award -Downstream Processing” at the BioProcess International Awards 2012.

Since 2006, BAC and GE Healthcare have worked closely together, developing products aimed at improving the efficiency of biopharmaceutical manufacturing.

With a focus on the development of affinity resins for highly efficient purification, the collaboration has led to the commercial launch of seven products which are now used worldwide in the manufacture of potentially life-saving medicines such as coagulation factors, various antibody formats, biosimilars and gene-therapy vectors.

Worldwide demand for biopharmaceuticals is set to increase, driven by an ageing population, rising obesity levels and the global effort to reduce the incidence of vaccine preventable diseases.

Laurens Sierkstra, CEO of BAC, said: “We are delighted to see our joint efforts to enable the development of the latest biotherapeutics recognized by those in the industry. Our on-going collaboration with GE Healthcare has been highly productive and responsive to the needs of end-users.”

Commenting on the award, Dr. Nigel Darby, Vice President of BioTechnologies, GE Healthcare Life Sciences added, “Collaborations between companies with complementary technologies and expertise are vital in making the advances that will help us tackle global challenges such as the increasing burden of disease and cost of healthcare. With global demand for cost effective biotherapeutics set to rise, collaborations like ours that deliver innovative supporting technologies will play an increasingly significant role.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BAC Completes Feasibility Study in Providing Selective Ligands for Genmab’s UniBody® Platform
BAC has successfully completed and delivered positive results from the initial feasibility study of its CaptureSelect® in collaboration with Genmab.
Thursday, September 30, 2010
BAC and Octapharma Extend Collaboration for G-CSF Custom Ligand for Commercial Scale Manufacture
Octapharma to use BAC’s G-CSF CaptureSelect® custom affinity ligand for the purification of recombinant human G-CSF from human cell cultures.
Thursday, August 19, 2010
BAC Affinity Ligand Licensed for Scale-up of LFB Biotechnologies’ Recombinant Factor VIIa
LFB Biotechnologies to use BAC’s anti-FVIIa CaptureSelect ligand for the purification of rhFVIIa from transgenic animals.
Thursday, April 15, 2010
BAC Extends Partnership with GE Healthcare to Launch Alpha-1 Antitrypsin Select
Extension reflects ongoing demand for BAC’s custom ligand and bioprocess products.
Thursday, February 18, 2010
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!